Major Depressive Disorder: Longitudinal Analysis of Impact on Clinical and Behavioral Outcomes in Uganda.

Journal: Journal of acquired immune deficiency syndromes (1999)

Volume: 78

Issue: 2

Year of Publication: 2019

Affiliated Institutions:  Mental Health Project, MRC/UVRI Uganda Research Unit on AIDS/Senior Wellcome Trust Fellowship, Entebbe, Uganda. School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Department of Psychiatry, Makerere College of Health Sciences, Kampala, Uganda. Butabika National Psychiatric Referral Hospital, Kampala, Uganda. Department of Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom. Department of Psychiatry, Stellenbousch University, Cape Town, South Africa. Health Service and Population Research, Centre for Global Mental Health and Primary Care Research, King's College, London, United Kingdom. Central and North West London NHS Foundation Trust, London, United Kingdom. Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA.

Abstract summary 

There is still wide variability in HIV disease course and other HIV-related outcomes, attributable in part to psychosocial factors such as major depressive disorder (MDD), a subject that has received little attention in sub-Saharan Africa.Using a longitudinal cohort of 1099 HIV-positive antiretroviral therapy-naive persons, we investigated the impact of MDD on 4 HIV-related negative outcome domains in Uganda. MDD was assessed using a Diagnostic Statistical Manual IV-based tool. Also collected were data on surrogate measures of the HIV-related outcome domains. Data were collected at the 3 time points of baseline, 6, and 12 months. Multiple regression and discrete time survival models were used to investigate the relationship between MDD and indices of the HIV outcomes.MDD was a significant predictor of "missed antiretroviral therapy doses" [adjusted odds ratio (aOR) = 4.75, 95% confidence interval (CI): 1.87 to 12.04, P = 0.001], "time to first visit to healthy facility" (aOR = 1.71; 95% CI: 1.07 to 2.73; P = 0.024), "time to first self-reported risky sexual activity" (aOR = 2.11, 95% CI: 1.27 to 3.49; P = 0.004) but not of "CD4 counts at months 6 and 12" (estimated effect 29.0; 95% CI: -7.8 to 65.7; P = 0.12), and "time to new WHO stage 3 or 4 clinical event" (aOR = 0.52, 95% CI: 0.12 to 2.20, P = 0.37).MDD significantly impacted 3 of the 4 investigated outcome domains. These results by demonstrating the adverse consequences of an untreated mental health disorder (MDD) on HIV-related outcomes further strengthen the need to urgently act on WHO's call to integrate mental health care in general HIV care.

Authors & Co-authors:  Kinyanda Eugene E Levin Jonathan J Nakasujja Noeline N Birabwa Harriet H Nakku Juliet J Mpango Richard R Grosskurth Heiner H Seedat Soraya S Araya Ricardo R Shahmanesh Maryam M Patel Vikram V

Study Outcome 

Source Link: Visit source

Statistics
Citations : 
Authors :  11
Identifiers
Doi : 10.1097/QAI.0000000000001647
SSN : 1944-7884
Study Population
Male,Female
Mesh Terms
Anti-HIV Agents
Other Terms
Study Design
Cohort Study,Longitudinal Study,Cross Sectional Study
Study Approach
Country of Study
Uganda
Publication Country
United States